Back to top
more

Acrivon Therapeutics, Inc. (ACRV)

(Delayed Data from NSDQ)

$7.47 USD

7.47
66,362

+0.02 (0.27%)

Updated Jul 15, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (162 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Verastem (VSTM) Begins Dosing in Solid Tumors Study in China

by Zacks Equity Research

Verastem (VSTM) doses the first patient in a phase I/II study conducted by GenFleet Therapeutics, evaluating KRAS G12D inhibitor, GFH375/VS-7375 in solid tumors. Shares rise.

AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU

by Zacks Equity Research

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.

SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why

by Zacks Equity Research

SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.

Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up

by Zacks Equity Research

Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion

by Zacks Equity Research

The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.

HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails

by Zacks Equity Research

HilleVax's (HLVX) phase IIb NEST-IN1 study evaluating HIL-214 for preventing acute gastroenteritis caused by norovirus infection in infants fails to meet its primary efficacy endpoint. Stock falls.

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why

by Zacks Equity Research

The recent label expansion of Mirum's (MIRM) lead drug, Livmarli, is expected to drive sales in the upcoming quarters. The company's efforts to build its pipeline beyond Livmarli also hold promise.

AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.

Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA

by Zacks Equity Research

The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.

SpringWorks (SWTX) Completes NDA Submission for Mirdametinib

by Zacks Equity Research

SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

by Zacks Equity Research

The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

by Zacks Equity Research

Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.

Corcept (CORT) Shares Rise 20% in Three Months: Here's Why

by Zacks Equity Research

Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.

GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance

by Zacks Equity Research

The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.

Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.

AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.

Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold

by Zacks Equity Research

Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies

by Zacks Equity Research

Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.

AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

by Zacks Equity Research

AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.

AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Imfinzi in combination with chemotherapy for treating mismatch repair deficient advanced/recurrent endometrial cancer based on data from the phase III DUO-E study.

Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry

by Zacks Equity Research

Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.

Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change

by Zacks Equity Research

Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.

Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug

by Zacks Equity Research

Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.

Ultragenyx (RARE) Posts New Data From Bone Disease Study

by Zacks Equity Research

Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.

SAGE's Huntington's Disease Study Meets Primary Endpoint

by Zacks Equity Research

The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.